Healthcare Industry News: Xeloda
News Release - March 15, 2006
Novacea Appoints Amar Singh as Chief Commercialization OfficerSOUTH SAN FRANCISCO, CA--(Healthcare Sales & Marketing Network)--Mar 15, 2006 -- Novacea, Inc. announced today that Amar Singh has been appointed chief commercialization officer. Mr. Singh joins Novacea from Abraxis Oncology, a proprietary division of American Pharmaceutical Partners, Inc., where he served as vice president of marketing and sales and successfully launched the anticancer agent, ABRAXANE(TM).
Mr. Singh will oversee all aspects of commercial strategy and implementation for Novacea's current product candidates, including DN-101, the company's lead product candidate in a Phase 3 clinical trial for advanced prostate cancer. "Amar brings with him an impressive track record of market development and commercialization of innovative oncology products," said Brad Goodwin, chief executive officer of Novacea. "He will add immediate value by helping us fully maximize the DN-101 opportunity as we conduct our Phase 3 program and move the product candidate toward the market. Amar will also be responsible for overseeing the effort to enhance our oncology portfolio through licensing and partnering deals, including seeking attractive currently commercialized products."
At Abraxis, Mr. Singh was responsible for all commercial operations where he built the sales, marketing, business solutions and medical executive teams and directed the successful launch of ABRAXANE. Prior to joining Abraxis, Mr. Singh served as executive director of new product planning, oncology marketing at Hoffmann-La Roche, Inc. where he led the launches of Xeloda®, a novel oral chemotherapeutic agent for the treatment of metastatic breast cancer, and KYTRIL®, an anti-nausea agent used in combination with oncolytics.
Mr. Singh holds a M.B.A. degree from New York University, and a B.A. in Economics from the University of North Carolina Chapel Hill.
Novacea, Inc. is a privately held biopharmaceutical company focused on in-licensing, developing and commercializing novel therapies for the treatment of cancer. Novacea's in-licensed product development programs include three clinical-stage oncology product candidates. The Company has one product candidate, DN-101, which is in a Phase 3 clinical trial for prostate cancer and a second product candidate, vinorelbine oral, which is expected to enter into a registration trial in late 2006 for the treatment of breast or lung cancer. Novacea's third product candidate, AQ4N, is expected to advance into a Phase 1/2 clinical trial in the second half of 2006 for the treatment of glioblastoma multiforme. For more information, visit www.novacea.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.